# US 2004/0001846 A1 · Prostate-specific membrane antigen and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001846 A1
- Document ID: US20040001846A1
- Status: Published application
- Kind: A1
- Application number: 10/443,694
- Filed: 2003-05-21
- Published: 2004-01-01
- Earliest claimed: 1995-02-24
- Assignees: Sloan-Kettering Institute for Cancer Research
- Inventors: Ron S. Israeli; Warren D.W. Heston; William R. Fair; Ouathek Ouerfelli; John Pinto
- Web page: https://patentgrep.com/patent/US20040001846A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 39/001195: {Prostate specific membrane antigen [PSMA]}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- G01N 2800/342: Prostate diseases, e.g. BPH, prostatitis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen. This invention provides a method of detecting a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen and a method of detecting a prostate tumor cell in a subject. Lastly, this invention provides a pharmaceutical composition comprising a compound in a therapeutically effective amount and a pharmaceutically acceptable carrier and a method of making prostate cells susceptible to a cytotoxic chemotherapeutic agent.

## Claims

### Claim 1

An isolated nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen.

### Claim 2 (depends on 1)

An isolated DNA of claim 1.

### Claim 3 (depends on 2)

An isolated cDNA of claim 2.

### Claim 4 (depends on 1)

An isolated RNA of claim 1.

### Claim 5 (depends on 2)

An isolated DNA of claim 2 operatively linked to a promoter of RNA transcription.

### Claim 6 (depends on 1)

A vector which comprises the nucleic acid of claim 1.

### Claim 7 (depends on 6)

A host vector system for the production of a polypeptide having the biological activity of the alternatively spliced prostate-specific membrane antigen which comprises the vector of claim 6 and a suitable host.

### Claim 8 (depends on 7)

A host vector system of claim 7, wherein the suitable host is a bacterial cell, insect cell, or mammalian cell.

### Claim 9

An isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen.

### Claim 10

An isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen.

### Claim 11 (depends on 10)

An antibody which specifically binds to the polypeptide of claim 10.

### Claim 12 (depends on 11)

The antibody of claim 11, wherein the antibody is monoclonal antibody.

### Claim 13 (depends on 11)

The antibody of claim 11, wherein the antibody is polyclonal antibody.

### Claim 14 (depends on 11)

The antibody of claim 11, wherein the antibody is labelled with a detectable marker.

### Claim 15 (depends on 14)

The labelled antibody of claim 14, wherein the marker is radioactive, or calorimetric, luminescent, or fluorescent marker.

### Claim 16

A method of detecting in a sample the presence of a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen which comprises: a) obtaining a suitable sample; b) extracting RNA from the sample; c) contacting the RNA with reverse transcriptase under suitable conditions to obtain a cDNA; d) contacting the cDNA under hybridizing conditions with two oligonucleotide primers,
i) the first primer being capable of specifically hybridizing to a sequence within a DNA sequence encoding prostate specific membrane antigen located immediately 3′ of nucleotide 114 of such DNA sequence, with the proviso that the 3′ end of the primer does not hybridize to any sequence located 5′ of nucleotide 114, and
ii) the second primer being capable of specifically hybridizing to a sequence within a DNA sequence encoding prostate specific membrane antigen located immediately 5′ of nucleotide 381 of such DNA sequence, with the proviso that the 5′ end of the primer does not hybridize to any sequence located 3′ of nucleotide 381;
d) amplifying any cDNA to which the primers hybridize to so as to obtain amplification product; e) determining the size of the amplification product; f) comparing the size of the amplification product to the size of the amplification product known to be obtained using the same primers with a non alternatively spliced human prostate specific membrane antigen, wherein a smaller amplification product is indicative of the presence of the alternatively spliced prostate specific membrane antigen, so as to thereby detect the presence of the alternatively spliced human prostate-specific membrane antigen in the sample.

### Claim 17

A method of detecting a prostate tumor cell in a subject which comprises: which comprises: a) obtaining a suitable sample; b) extracting RNA from the sample; c) contacting the RNA with reverse transcriptase under suitable conditions to obtain a cDNA; d) contacting the cDNA under hybridizing conditions with two oligonucleotide primers,
i) the first primer being capable of specifically hybridizing to a sequence within a DNA sequence encoding prostate specific membrane antigen located immediately 3′ of nucleotide 114 of such DNA sequence, with the proviso that the 3′ end of the primer does not hybridize to any sequence located 5′ of nucleotide-114, and
ii) the second primer being capable of specifically hybridizing to a sequence within a DNA sequence encoding prostate specific membrane antigen located immediately 5′ of nucleotide 381 of such DNA sequence, with the proviso that the 5′ end of the primer does not hybridize to any sequence located 3′ of nucleotide 381;
d) amplifying any cDNA to which the primers hybridize to so as to obtain amplification product; e) determining the amount of the amplification product; f) comparing the amount of the amplification product to the amount of the amplification product known to be obtained using the same primers with a non alternatively spliced human prostate specific membrane antigen, wherein a greater amount of the prostate specific membrane antigen is indicative of a prostate tumor cell in the subject, so as to thereby detect prostate tumor cell in the subject.

### Claim 18

A compound comprising a conjugate of a cytotoxic agent and one or more amino acid residues, wherein each amino acid residue is glutamate or aspartate.

### Claim 19 (depends on 18)

The compound of claim 18, wherein the compound has the structure:
4
wherein n is an integer from 1-10 inclusive.

### Claim 20 (depends on 18)

The compound of claim 18, wherein the compound has the structure:
5
wherein n is an integer from 1-10 inclusive.

### Claim 21 (depends on 18)

The compound of claim 18, wherein the compound has the structure:
6
wherein n is an integer from 1-10 inclusive.

### Claim 22 (depends on 18, 19, 20, 21)

A pharmaceutical composition comprising the compound of any of claims 18-21 in a therapeutically effective amount and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 18, 19, 20, 21)

A method of making prostate cells suseptible to a cytotoxic chemotherapeutic agent, which comprises contacting the prostate cells with an the compound of any claims 18-21 in an amount effective to render the prostate cells suseptible to the cytotoxic chemotherapeutic agent.
